The Latest
-
Karissa Waddick/Industry Dive
Emerging biotechYoung startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
-
hirun via Getty Images
Sponsored by PharmaForceIQPharma marketers need a share-of-answer strategy before AI spend
AI is changing how HCPs seek answers. Pharma marketers need a new strategy.
-
Getty Images
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Following a $1.5 billion licensing deal with stealthy startup Sentivera, Haisco Pharmaceutical now ranks among the sector's most prolific China-based partners since the start of 2025, BioPharma Dive data show.
Updated Aug. 25, 2026 -
Getty Images
News roundupZepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
-
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
-
Sarah Silbiger via Getty Images
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
-
Permission granted by Roche
Obesity drugsRoche commits to lean-mass preservation with Hanmi obesity deal
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
-
Getty Images
Obesity drugsHow cost and perception could reshape the GLP-1 market
As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.
-
Getty Images
VaccinesCancer vaccine win restores Wall Street’s faith in Moderna
Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
-
Getty Images
News roundup
FDA extends review of Capricor cell therapy; Pain drug startup to go public
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
So far in 2026, RA Capital and OrbiMed again rank as the most active investors tracked by BioPharma Dive. But multiple corporate venture arms are in the top 10 this year as well.
Updated Aug. 13, 2026 -
Getty Images
Regeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
-
Sundry Photography via Getty Images
Ultragenyx, after setbacks, nabs first gene therapy approval
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
-
Getty Images
News roundup
Shareholder pressures Capricor; Lilly dives deeper into vaccines
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.
-
Getty Images
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
-
Sarah Silbiger via Getty Images
Trump administrationTrump nominates policy aide Overton to lead FDA
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
Updated Aug. 19, 2026 -
Permission granted by Amylyx Pharmaceuticals
Amylyx’s bet on a GLP-1 blocker pays off
A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
BioMarin’s planned purchase of Alesta Therapeutics brings the tally of bigger-ticket acquisitions of rare disease drugmakers to half a dozen this year.
Updated Aug. 10, 2026 -
Getty Images
VaccinesFDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
-
Getty Images
BioMarin acquires experimental drug for rare bone disorder in $275M deal
The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
-
Alamy
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
-
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
-
Getty Images
Leo Pharma buys rare skin disease drug in $435M deal
Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.
Updated Aug. 7, 2026 -
Permission granted by Image courtesy of Formation Bio
ProfileFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
